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Abstract
The mitochondrial protease OMI (also known as HtrA2) has been implicated in Parkinson’s Disease (PD) and deletion or
protease domain point mutations have shown profound neuropathologies in mice. A beneficial role by OMI, in preserving cell
viability, is assumed to occur via the avoidance of dysfunctional protein turnover. However relatively few substrates for
mitochondrial Omi are known. Here we report our identification of three novel mitochondrial substrates that impact
metabolism and ATP production. Using a dual proteomic approach we have identified three interactors based upon ability to
bind to OMI, and/or to persist in the proteome after OMI activity has been selectively inhibited. One candidate, the chaperone
HSPA8, was common to each independent study. Two others (PDHB subunit and IDH3A subunit) did not appear to bind to
OMI, however persisted in the mito-proteome when OMI was inhibited. Pyruvate dehydrogenase (PDH) and isocitrate
dehydrogenase (IDH) aretwo key Kreb’s cycle enzymes that catalyseoxidative decarboxylation controlpointsin mitochondrial
respiration. We verified both PDHB and IDH3A co-immunoprecipitate with HSPA8 and after elution, were degraded by
recombinant HtrA2 in vitro. Additionally our gene expression studies, using rotenone (an inhibitor of Complex I) showed Omi
expression was silenced when pdhb and idh3a were increased when a sub-lethal dose was applied. However higher dose
treatment caused increased Omi expression and decreased levels of pdhb and idh3a transcripts. This implicates mitochondrial
OMI in a novel mechanism relating to metabolism.
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Introduction
Omi (HtrA2/PARK13) was originally identified as a homo-
logue of a bacterial protease HtrA [1]. In mammalian cells, the
nuclear-encoded OMI resides in the inter-membrane space (IMS)
of mitochondria as active, mature (32–36 kD) and pre-processed
50 kD forms. A second pool of OMI resides on the ER [2]. OMI
activity is induced by stress, causing auto-catalysis at A
133 [3]. This
facilitates release into the cytosol, removing a trans-membrane
domain and exposing a domain that binds with the most studied
OMI substrate, the anti-apoptotic factor XIAP. OMI precipitates
apoptosis by binding and degrading XIAP, causing the release and
subsequent activation of caspases [4]. In addition it’s protease
activity in the cytosol may contribute by selective turn-over of key
proteinaceous substrates [4,5] (for a review please see [6]).
Our interest is in the mitochondrial role of OMI in
neurodegenerative disorders. OMI is a homo-trimer, where each
monomer consists of a MLS, a small trans-membrane region, the
AVPS sequence (for XIAP interaction), the protease domain and
the PDZ domain (governing substrate interaction) [4,5,7–15].
Mitochondrial dysfunction is coincident with PD [16] and in
humans Omi deficiencies have been found in PD patients [17]. In
addition OMI has been consistently detected in Lewy Bodies (LB) -
the intracellular aggregates that represent one of the hallmarks of
PD and LB Dementia [18]. Two other studies have strongly
contested any genetic implication of Omi with PD [19,20],
nevertheless animals with a lack of this protease show a profound
neuropathology. The mnd2 mutation, that spontaneously arose as
an autosomal recessive disorder was identified as a mis-sense
mutation (S276C) in the protease domain [21,22]. It manifest as
abnormal spinal motor neuron morphology and muscle denerva-
tion leading to muscle atrophy and progressive paralysis [21].
Neurodegeneration of striatal neurons occurred around 3 weeks of
age, accompanied by astrogliosis and the activation of microglia
with animals rarely living past 40 days p.n. [22]. The protease
activity of Omi was greatly reduced in the tissues of mnd2 mice,
albeit restored by a partial deletion in the PDZ domain, indicating
substrate binding may have been a root cause. Additional studies
using targeted deletions of the mouse Omi gene (Prss25) developed
a parkinsonian phenotype with loss of striatal neurons [23].
Simultaneous deletion of another predominant IAP-binding
protein did not alter the animal or cellular phenotype, indicating
it was the protease activity of Omi that was beneficial, rather than
the IAP interaction. With respect to its mitochondrial function,
recent reports have given some clues. The loss of Omi in the brain
was shown to cause an accumulation of unfolded mitochondrial
proteins and ROS, which could signal the increased expression of
the transcription factor CHOP. CHOP expression is a part of the
Integrated Stress Response (ISR) and was seen to be increased in
PD patients [24]. Although most studies place the role of OMI in
the maintenance of the mito-proteome and the avoidance of ROS
accumulation, there are few known mitochondrial substrates.
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substrates [6] with the only known mitochondrial substrate
HAX-1 (an anti-apoptotic factor) keeping the focus upon OMI
as a death effector [25]. Recently mitochondrial APP was reported
to be a substrate, cleaved by either mature or immature OMI in
the mitochondrion, furthering the importance of this protease in
neuronal function [26].
OMI, as a substrate of other enzymes such as Akt, Rhomboid-7
and Pink-1 [27–29], has led to proposed regulatory mechanisms
for this serine protease. In particular, mutations in the kinase Pink-
1/PARK6 are a known cause of familial PD, with aberrant
mitochondrial morphology clearly exhibited in mammalian cells
[30]. Pink-1 has been shown to interact with OMI and
phosphorylate several key amino acid residues leading to increased
OMI activity [28]. Additionally Parkin/PARK2, another gene
with mutations known to cause familial PD, had been shown to
rescue Pink-1 mutations [30]. All of this has led to a multi-factorial
mechanism for maintaining mitochondrial integrity, where the
role of OMI was downstream of Pink-1 (which in turn was
upstream of Parkin), but was independent of Parkin [29,31,32].
While no consensus has been reached, it appears likely that both
Omi and Parkin act via parallel pathways, with respect to Pink-1,
in maintaining mitochondrial integrity. The added importance of
the ATP-dependent mitochondrial Rhomboid-7 was shown by its
ability to co-immunoprecipitate and cleave both PINK1 and OMI
into mature forms that are no longer membrane-tethered [29]. In
this way Rhomboid-7 (or its human homologue PARL) could be
seen as an activator of both enzymes during times when ATP was
not limiting.
Our main interest was in discerning the mitochondrial
substrates of OMI. In this study, we used two approaches
(functional and structural) to discover three novel substrates, one
of which is the chaperone for the other two, which are subunits of
regulatory Kreb’s cycle enzymes. We then studied the coincidental
expression of these players under lethal and sub-lethal conditions.
From our results, we hypothesize a novel mechanism for the role
of Omi in the mitochondrion, which may account for its beneficial
role and contribution to neurodegenerative processes, and move
Omi beyond protein quality control.
Results
Degradomic approach using the mito-proteome and OMI
inhibitor ucf-101
Differential proteomic samples were generated by incubating
mitochondria, isolated from HEK293 cells, in the presence or
absence of the serine protease inhibitor, ucf-101 for 2H under
aerobic conditions. Isolated mitochondria were used because a
previous report had shown non-specific cellular effects of ucf-101
[33]. Inhibitor concentrations were chosen from the literature and
following incubation trials with immunoblotting to detect
persistence of the OMI substrate, HAX-1 (figure 1A) [34]. IEF/
2D electrophoresis of concentrated mitochondrial proteins dis-
cerned several protein species that persisted in greater amounts
when OMI was inhibited (figure 1B). Several were arbitrarily
chosen, manually cored and sent for analysis via in-gel trypsin
digestion and MS-MS (Rockefeller Core). This method has
limitations in that it represents a small sub-set of proteins that
were potentially cleaved by OMI. The table of those identified
samples that were of particular interest to us (Table 1) included
subunits of two Kreb’s Cycle enzymes (PDHB and IDH3A)). The
third identified protein was HSPA8 (also known as heat shock
70 kDa protein 8, HSP73, HSPA10, constitutive heat shock
protein 70, heat shock cognate protein, 71-kDa, for nomenclature
guidelines see [35]). We then verified these proteins by
immunoblot detection (normalized for total mitochondrial protein)
as shown in figure 1C.
Structural ‘‘entrapment’’ approach using the mito-
proteome and tagged OMI
Proteins that directly interacted with OMI, were isolated and
identified using an approach that exploited the trimeric shape of
OMI to ‘‘trap’’ substrates. A similar approach had been used with
the large, bacterial multimeric protease ClpP/X [36]. We
enriched for two pools of proteins that were co-immunoprecipi-
tated with FLAG-tagged OMI protease mutants. These OMI
mutants had either an inactive site, or the same active site
mutation accompanied by a mutated PDZ domain (figure 2A).
The first mutant OMI would entrap substrates within the trimer’s
cleft, whereas the second mutant could not due to a mutation in
the PDZ domain. This mutation disallowed the conformational
change giving substrate access. Any species isolated via this double
mutant represented those binding to the OMI trimer either non-
specifically, or specifically (but not as a substrate for cleavage).
IEF/2D electrophoresis of concentrated mitochondrial proteins
and comparison of protein spots detected in the former (OMI
S306C/FLAG) but not the latter (OMI S306C.G399S/FLAG)
showed several unique species. These were manually cored and
identified via in-gel trypsin digestion and tandem MS (Cornell,
Ithaca Core Facilities). A representative gel for both mutant pull-
down experiments shows some of the samples sent for identifica-
tion in figure 2B. The combined results are tallied in table 1. These
results revealed that the heat shock cognate protein was common
to both the FLAG/IP pull-down approach and the ucf-101 studies.
This provided strong evidence that HSPA8 was affected by the
protease activity of OMI and directly interacted with the enzyme.
Validation of candidates’ ability to interact with HSPA8
and be degraded by HtrA2
We investigated co-precipitation of PDH and IDH using
specific HSPA8 antibodies. Previous studies in a non-neuronal
system, had linked PDH with HSP70, showing co-immunopre-
cipitation of PDH when anti-HSP70 was used, and vice versa [37].
Mitochondrial isolates were used to eliminate cytosolic interactors
and, in the case of IDH, cytosolic isozymes. The results, showed
small but detectable amounts of each interactor with the
endogenous HSPA8 (figure 3A). In all cases the protein species
identified appear slightly larger than predicted, but within the
appropriate pI range. We then tested whether OMI could digest
PDH and IDH subunits. An in vitro assay was used, where the co-
IP eluted samples were divided into two parts, each being
incubated with recombinant HtrA2/Omi in the presence or
absence of 40 uM ucf-101. Figure 3B shows a representative
immunoblot probed for PDHB and IDH3A. In both cases the
presence of the OMI inhibitor ucf-101 allowed the persistence of
both species of endogenous HSPA8 interactors from isolated
mitochondria. To confirm this interaction using exogenous
HSPA8, we transfected HA-tagged HSPA8 with OmiS306C/
G399S over-expression or the empty vector (BH4). As a control we
included another mitochondrial chaperone HSPD1. The resulting
hetero-trimers of OMI (formed with both the endogenous active
and introduced inactive monomers) were a means of increasing
detection under these conditions. A representative immunoblot of
the pull-down (Figure 3C) showed all three species were detected.
Comparatively greater amounts of OMI were seen when the
mutant OMI was over-expressed as expected, due to the antibody
not distinguishing between the endogenous and exogenous forms.
Novel Substrates of Omi
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protein normalized samples from the double mutant. More
detailed studies on the nature of each of the interactions are
required in order to explain this.
Relevance to neuronal damage
Fluctuations in gene expression often reflect adaptive changes in
the proteomic profile of the cell. To further evaluate OMI and
these novel interactors, we chose to study their gene expression in
during neuronal stress. We investigated omi, pdhb, hspa8, and idh3a
gene expression in an established cell model for PD, with all
samples normalized to b-actin. Human neuroblastoma (SH-SY5Y)
cells treated with the dopamine neurotoxin 6OHDA (100 mM)
showed an increase in omi gene expression above the untreated
control by 2 hours (figure 4A). This reached a maximum of 143%
at 3 hours and was maintained above control levels for up to
24 hours post-treatment. Mitochondria isolated at 24 hours post-
treatment showed an increase in OMI protein relative to its
Figure 1. Inhibition of HAX-1 degradation by native OMI in HEK293 cells. (A) Immunoblot of mitochondrial proteins showing increased
persistence of HAX-1 with increased concentration of the OMI inhibitor ucf-101. (TIM23 is shown as a loading control). (B) Silver stained IEF/2D gel of
mitochondrial proteins present after isolated mitochondrial samples were divided into two equal parts and incubated in the presence or absence of
ucf-101. Arrows indicate species that persisted when the inhibitor ucf-101 was included. (C) Immunoblot of mitochondrial samples validating the
increased persistence of PDHB and IDH3A in the presence (+) of ucf-101.
doi:10.1371/journal.pone.0007100.g001
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indicating the increased gene expression led to greater amounts
of functional protease. We also found altered hax-1 expression. As
with omi, hax-1 showed a similar, early increase in expression
although this lagged omi expression by at least one hour (figure 4A).
Maximal hax-1 expression (136%) level was also seen at 3 hours
however, unlike omi expression, was not maintained. In order to
discern if this were an omi-specific effect, the gene expression of
another mitochondrial protease, paraplegin (spg7), was tested
(figure 4A). Its expression appeared to have a bi-phasic response to
6OHDA treatment and, unlike omi, was reduced in the first
6 hours of receiving treatment. Expression dropped to approxi-
mately two thirds of the untreated control within the first 2 hours,
with gradual increase to 75% and 85% at 3 and 6 hours
respectively. The second phase showed an increase to 150% and
as high as 182% of control during the next 12 hour period. These
dissimilar patterns between the two proteases, showed the
6OHDA treatment effect on omi was gene-specific.
Further studies showed this pattern was also toxin-dependent
and not a general stress response. When either the proteosome
inhibitor MG-132 (1 uM) or the mETC inhibitor, rotenone
(100 nM) were used, neither omi nor hax-1 gene expression
followed the same pattern as during 6OHDA toxicity (figure 4C).
MG-132 toxicity resulted in an increase in omi gene expression at
12 hours post-treatment. Other time points that differed signifi-
cantly from the untreated control were at 24 and 48 hours, when
omi expression was reduced. The overall pattern of omi expression
during inhibition of cytoplasmic protein turnover by MG-132 was
in stark contrast to that seen with 6OHDA treatment. Likewise
rotenone treatment showed an early increase in omi gene
expression above that seen with the untreated control. This
fluctuated greatly over the 48 hour time period, returning to
control levels by 48 hours, with maxima seen at 12 and 24 hours.
Comparison between MG-132 and rotenone treatments showed
only two time points with a common omi expression response
namely, the control-level expression seen at 6H post-treatment,
and the coincidental peak in expression at 12 hours. When we
compared the peak with hax-1 expression at 12 hours, rotenone
and MG-132 treatment both gave a large increase in omi
expression (205% and 194%), coinciding with a dramatic decline
in hax-1 expression (47% and 9%) respectively. By contrast, neither
of these changes was seen at 12 hours with 6OHDA treatment,
where hax-1 expression had already returned to control levels.
The expression of our novel OMI interactors also altered with
the neurotoxin treatment. Quantitative PCR results showed that
initially the level of hspa8 remained at the same level as the
untreated control cells, but after 3 hours was increased to a greater
magnitude than that seen with omi (Figure 5). Omi expression was
elevated up to 143% by 3 hours, whereas hspa8 expression did not
peak until 12–18 hours at which point it was more than 217% of
the untreated control. Gene expression of both idh3a and pdhb was
diminished. After an initial increase at 2 hours, the expression of
pdhb stayed mostly at untreated levels with a drop down to
approximately 73–86% at 12 and 18 hours post-treatment,
whereas idh3a had declined to 70% of the untreated gene
expression levels by 2 hours and remained at this or lower for
the remainder of the sampling period. This result implied that
there was some degree of regulation in the expression levels of
these subunits of two Kreb’s Cycle enzymes, in response to the
oxidative stress resulting from the 6OHDA treatment. However
the general, decreased expression of pdhb and idh3a while omi
expression was increasing, warranted further investigation.
Further gene expression studies
The 6OHDA cell model used above represented severe,
neurotoxic conditions. We also looked at omi, pdhb, idh3a and
hspa8 gene expression during conditions when oxidative phos-
phorylation (OXPHOS) capacity was challenged, but not severely
compromised. During sub-lethal inhibition of complex I by
rotenone, the pressure from continued Kreb’s cycle turn-over
would be most apparent at complex II. Our novel OMI substrates
included subunits of mitochondrial (mt)IDH (catalyzing the
immediate step before succinate dehydrogenase) and PDH
(supplying acetyl CoA to the Kreb’s cycle). We hypothesized the
expression of these interactors would be good barometers for
change under sub-lethal (10 nM) rotenone treatment. Gene
expression patterns of the three identified interacting proteins in
HEK293 cells (Figure 6) showed omi expression began decreasing
at 1 hour post-treatment, after which it decreased markedly at 3
and 12 hour time points (33% and 14% respectively). The 6 hour
sample showed expression not unlike the uninhibited control. By
contrast pdhb expression was increased at those times when omi was
maximally diminished (3H and 12H). Likewise, idh3a showed its
greatest expression at 3 hours (148%), after an initial decrease at 1
hour. Expression of the chaperone hspa8 showed a trend towards
increased expression at 3 hours. However by 6 hours, expression
was significantly diminished to less than half of the uninhibited
control, just as omi was increasing back up to control levels. At
12 hours hspa8 expression was increased again, while omi
expression was diminishing. The overall trend seen with sub-
lethal rotenone treatment was to cause increased or decreased
expression of the three OMI substrates, when omi expression itself
was decreasing or increasing respectively.
Discussion
Our analysis of the mitochondrial degradome (in the presence/
absence of OMI inhibitor ucf-101) allowed the discovery of novel
OMI substrates important to aerobic respiration. The third substrate
was a specific chaperone, HSPA8. We also identified the same
chaperone via the ‘‘entrapment’’ approach, using FLAG-tagged
mitochondrial OMI. This allowed pursuit of the relationship between
the four proteins. Previous work by others in different cell types had
shown PDH was a binding partner with HSP70. It is worth noting
Table 1. Proteins identified via MS-MS.
Functional Proteomic Approach
accession gene and protein name
P11142 HSPA8 Heat shock cognate 71 kDa protein (Heat shock 70 kDa
protein 8)
P11177 PDHB Pyruvate dehydrogenase E1 component beta subunit,
mitochondrial precursor (EC 1.2.4.1)
P50213 IDH3A Isocitrate dehydrogenase [NAD] subunit alpha,
mitochondrial precursor (EC 1.1.1.41)
P07195 LDHB L-lactate dehydrogenase B chain (EC 1.1.1.27)
P08107) HSPA1 Heat shock 70 kDa protein 1
Structural (substrate trap) Proteomic Approach
P11142 HSPA8 Heat shock cognate 71 kDa protein (Heat shock 70 kDa
protein 8)
P30101 PDIA3 N-terminal of the glycoprotein chaperone ERp57 (chain A)
(EC 5.3.4.1)
Table depicting the identified proteins from spot excision of the silver-stained
IEF/2D gels in the functional and substrate trap proteomic approach.
doi:10.1371/journal.pone.0007100.t001
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similarity to the stress-inducible HSP70. Both are members of a large
family of heat shock proteins. Despite their abundance in the cytosol,
and in association with and in mitochondria, we did not identify
HSP70 or any other related heat shock family members beyond the
homologous sub-regions of the HSPA8 sequence.
Using isolated mitochondria, we have shown the HSPA8-
specific antibody was able to co-immunoprecipitate small amounts
of IDH3A and PDHB. Our studies employed IEF/2D separation
due to the small amounts of protein involved, as well as the weaker
epitope-interaction by the HSPA8 antibody. In doing so, we have
established a new, potential role for endogenous HSPA8, distinct
from its many cytosolic roles, as being that of transporting IDH3A
and PDHB to the mitochondrion. Additionally, when the
immunoprecipitated species was incubated with recombinant
HtrA2 there was degradation unless the inhibitor ucf-101 was
Figure 2. Results from the entrapment approach used to identify mitochondrial proteins interacting with OMI. A cartoon depicting
OMI as a trimer with the regulatory PDZ domain (A). A representative silver stained IEF/2D gel of mitochondrial proteins from HEK293 cells
transfected with FLAG-OMI mutant and immunoprecipitated with anti-FLAG beads (B). Arrows indicate the species that were unique to the OMI306
mutant but not common to both OMI.S306C and OMI.S306C/G399S.
doi:10.1371/journal.pone.0007100.g002
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PLoS ONE | www.plosone.org 5 September 2009 | Volume 4 | Issue 9 | e7100Figure 3. Validation of candidates’ ability to interact with HSPA8 and be degraded by HtrA2 Representative immunoblots (A) of
IEF/2D separated, post-IP mitochondrial proteins from HEK293 cells expressing the FLAG.OMI.S306C mutant. Arrows indicate
immunoreactive spots according to the antibody used. (B) Samples were also incubated in the presence/absence of ucf-101 with recombinant HtrA2/
OMI and separated and immunoblotted as above. Arrows indicate the species that correlated to the results in (A) and that persisted in the presence
of ucf-101, but were absent without inhibition of OMI. (C) Immunoblots of anti-HA immunoprecipitated proteins. Arrows indicate immunoreactive
spots according to the antibody used. HA.HSPD1 was used as a mitochondrially-targetted HA-tagged protein control.
doi:10.1371/journal.pone.0007100.g003
Novel Substrates of Omi
PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7100Figure 4. Gene expression studies of omi, hax-1 and spg7 (paraplegin) in SH-SY5Y cells treated with 100 mM 6OHDA (A). Expression is
normalized for b-actin and shown as a percentage of the untreated control (UnTx). (B) Representative immunoblots showing the level of OMI and
HAX-1 in untreated and 6OHDA-treated SH-SY5Y cells. (C) Gene expression studies of omi and hax-1 in SH-SY5Y cells treated with the proteasome
inhibitor MG132 (1 mM) or Complex I inhibitor Rotenone (100 nM). Expression is shown as a percentage of the untreated control (UnTx) where all data
is the Mean6SEM: n$3, and where * indicates P#0.005 and ** indicates P#0.05 (using two tailed t-test analysis).
doi:10.1371/journal.pone.0007100.g004
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tagged HSPA8 co-immunoprecipitation studies. All three species
(OMI, PDHB and IDH3A) were co-precipitated to varying
degrees. We concluded that both subunits can be bound by
HSPA8 and all three proteins may be degraded by OMI at or
inside the outer membrane of the mitochondrion. More direct
evidence of this physical interaction was seen in a report
investigating Lewy Bodies (LBs), the proteinaceous aggregates
formed in PD brains. Clearly visible within tissue sections, LBs are
mostly comprised of a-synuclein, and are a histopathological
hallmark of PD. Using laser capture micro-dissection to study the
other protein components in LBs from PD brains, HSPA8 was
identified as one of the major components within these aggregates
[38]. Additionally Kawamoto et al. showed increased OMI
present in inclusion bodies of neural cells in the tissue of patients
with a-synucleinopathies [18]. These two independent studies
establish that aberrant levels of both proteins (OMI and HSPA8)
occur in PD brains, supporting our results that show the
relationship between them.
Establishing the conditions where this relationship is relevant
and how it could be tested was made difficult by the roles of both
OMI and HSPA8. Each may be located or re-located to two other
major compartments of the cell, namely the cytosol and
endoplasmic reticulum. In addition, the death effector role of
OMI disallows over-expression studies.
In this current study, and in relation to PD, we have shown
neurotoxicity (caused by 6OHDA) increased omi transcription in
neuroblastoma cells, and with this came a coincidental, relative
decrease in the novel OMI substrates. We believe this to be an
initial, protective role of mitochondrial OMI. Under conditions of
acute 6OHDA toxicity, the increased ROS production via
OXPHOS establishes a strong incentive to shift away from using
the Kreb’s cycle for anabolic components and energy production.
Under these conditions, the need to limit ROS production causes
an increase in OMI, so it might degrade the incoming regulatory
subunits of Kreb’s cycle enzymes PDH and mitochondrial IDH.
While this may initially be protective, continued stress would
reverse OMI’s beneficial role, making the release of activated
OMI and other death-effectors from the damaged mitochondrion
inevitable.
Poisoning by 6OHDA provided an acute and severe condition
in which to study omi expression. Further from this, we chose
conditions where OMI activity would not be ideal, namely when
OXPHOS was restricted (in the absence of excess oxidative
damage) and substrate availability was not limiting. Under these
conditions, we proposed greater flux through the regulatory steps
of the Kreb’s cycle would be beneficial. By using partial inhibition
of complex I by rotenone, we placed greater demand on complex
II to provide for OXPHOS which in turn would make increased
IDH and PDH activity more desirable. We postulated this would
elicit effects on omi gene expression, given that OMI could degrade
IDH3A and PDHB. Our results showed a transient silencing of omi
expression, which was coincident with increased expression of the
novel OMI substrates. This suggested conditions where omi
expression (and potentially OMI activity) was not beneficial, just
as the early stage of 6OHDA neurotoxicity suggested a time point
when it was.
Further experiments to discern the regulatory players in this
altered omi expression are required. Interestingly studies investi-
gating the cleavage of CIAP (a member of the IAP family)
identified OMI as the serine protease involved, and found
expression of omi was increased upon activation of the transcrip-
tion factor p53 [39]. This established omi as a downstream target
gene of p53 and the presence of a p53 dependent apoptotic
pathway in mammals. While this pathway operates in the cytosol
and directly impacts cytosolic OMI, it is possible that p53 plays a
role in our toxicity studies where the effects are initiated in the
mitochondrion and lead to increased omi gene expression.
Figure 5. Gene expression studies of omi, idh3a, pdhb and hspa8 in SH-SY5Y cells treated with 100 mM 6OHDA. Expression is normalized
for b-actin and shown as a percentage of the untreated control (UnTx) where all data is the Mean6SEM: n$3, and where * indicates P#0.005 and
** indicates P#0.05 (using two tailed t-test analysis).
doi:10.1371/journal.pone.0007100.g005
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normalized for b-actin and shown as a percentage of the untreated control (UnTx) where all data is the Mean6SEM: n$3, and where * indicates
P#0.005 and ** indicates P#0.05 (using two tailed t-test analysis).
doi:10.1371/journal.pone.0007100.g006
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in our sub-lethal studies, also mediated by the mitochondrial
demands, requires greater investigation.
Until this study, the beneficial role of OMI in the mitochon-
drion has largely been considered as one of maintaining protein
quality and turn over. A model recently postulated by Plun-
Favreau et al. suggested the mitochondrial kinase PINK1
mediated OMI’s activity. In this model PINK1 kinase activity
was thought to increase proteolytic capability of OMI, and protect
cells from stress-induced mitochondrial dysfunction [40]. The
same researchers found PD patients had considerably less OMI in
which its key site (OMI S
142) was phosphorylated by PINK1 [28].
Their model described cells with OMI trimers that contained one
or more monomers lacking S
142 phosphorylation, would be more
vulnerable to mitochondrial stress. Additionally they found that
idiopathic PD tissue showed greater amounts of phosphorylated
OMI compared with normal controls. This implied PINK1 and
OMI/HtrA2 operated within a dynamic stress-sensing model,
although it could not be determined whether high levels of PINK-
activated HtrA2 were a protective response or a cause of nigral cell
death. Further to this model is a second protease known as
Rhomboid-7 in drosophila and its orthologue PARL in mammals.
Whitworth et al discovered Rhomboid-7 was capable of binding
both OMI and PINK1, as well as cleaving them in their different
intramembrane domains [29]. This provides an additional
regulatory means of increasing the mobile pool of both proteins
in the intermembrane space. Whether this translates to more or
less OMI for cleaving IMS or membrane-associated proteins
(respectively), or whether this directly impacts the interaction
between OMI and PINK1, remains to be tested. Since PARL is
ATP-dependent, where OMI is not, it represents an intriguing
aspect of regulation to the PINK1-HtrA2 stress response model.
Our results provide a new piece in this puzzle of describing the
role of OMI in the mitochondrion. We believe this protease to be a
regulator of IDH3A and PDHB entering the organelle and suggest
it is most likely working from a baseline level of activity, so the
mitochondrion may be poised to respond according to demand.
While OMI is unlikely to be the only regulator, its ability to
function independent of ATP should not be overlooked,
particularly when key players, such as other mitochondrial
proteases, are largely ATP-dependent. Regulation of OMI activity
can now be sub-divided between autocatalysis (from inactive to
active), PINK1 phosphorylation (from baseline to activated) and
Rhomboid-7 modification (from membrane to IMS localization).
Our model adds further to the PINK1-HtrA2 stress-sensing
model. We suggest, as part of the stress-sensing model, that a pool
of deficient or over-active OMI would be deleterious when there is
a need to switch between OXPHOS and substrate-level
phosphorylation, whether this may be due to a need to avoid
excessive ROS production, or a need to generate more ATP. In
the case of too much (or aberrantly activated) OMI, the chaperone
role of HSPA8 would be destroyed, which could potentially limit
PDH and mtIDH activity. This situation may also precipitate the
re-location of OMI into the cytosol along with other toxic cell
changes, depending upon the type of cell, its metabolic needs, and
the duration of the demands placed upon it. In the case where
OMI activity was absent or unable to be activated (due to PINK1
deficiencies) during conditions of less demand (but when substrates
were plentiful), there would be little or no protease capable of
controlling IDH3A and PDHB import. With one less control
mechanism, the continued activity and pressure on OXPHOS
would generate greater ROS accumulation. Two such paradigms
exemplifying the second case may present as #1. fast-firing,
dopaminergic neurons (with their need to rapidly restore
conditions after repetitive, sequential firing of action potentials)
or #2. the developing mnd2 mouse-pup. The former situation is
further complicated by calcium ion fluctuations to levels capable of
activating both of these Kreb’s cycle enzymes, which would
exacerbate the pressure on OXPHOS. Under these conditions,
PINK1 would have a positive role in maintaining OMI activation,
and subsequently its substrates greater degradation. The role of
Rhomboid-7 requires greater scrutiny in our model. However, it is
tempting to suggest that Rhomboid-7 processing would rid the
mitochondrial membrane of its tethered OMI pool, which could
only be replenished by newly synthesized OMI. As such, over or
under-active Rhomboid-7 would impact our model in an ATP-
dependent manner.
Several key experiments still need to be addressed, including
determining the HSPA8, IDH3A and PDHB levels and expression
patterns in the mnd2 developing mouse brain. Our current
research also focuses on establishing a cellular assay in which
the manipulation of OMI activity and its impact on Kreb’s cycle
function and ROS accumulation can be measured. We include the
use of Omi phosphomutants to further establish the effect of
PINK1 activation of OMI on our novel substrates. Likewise future
studies with OMI mutants unable to be cleaved by Rhomboid-7/
PARL could further improve our understanding of the involve-
ment of mitochondrial OMI in the pathogenesis of PD.
Materials and Methods
Cell culture, transfection and isolation of mitochondria
Cells (HEK-293 and SH-SY5Y, ATCC) were grown in 10%
FBS/DMEM supplemented with 20 U/mL penicillin and 20 ug/
mL streptomycin at 37uCi n5 %C O 2/95% air. Small wells were
transfected using lipofectamine following the manufacturer’s
protocol. Cells on large plates (150 cm) were transfected using
the Calcium Phosphate method [41]. Detachment of cells was
achieved with 10 mM EDTA treatment, followed by centrifuga-
tion and resuspension of the pellet in mitochondrial isolation
medium (1 mM EDTA, 10 mM HEPES, 250 mM sucrose,
pH 7.4). Cells were permeabilised using digitonin (400 ng/mL)
incubation and then ruptured by homogenisation in a Dounce
glass homogenisor. Cell debris was removed by centrifugation at
5000 Xg. The supernatant was centrifuged at 12000 Xg to form a
crude mitochondrial pellet. Protein estimations were done using
the BCA protein assay kit (Pierce #23225). Isolated mitochondria
were divided into two equal parts and incubated in reaction
medium (250 mM sucrose, 10 mM MOPS, 10 mM KH2PO4,
5 mM MgCl2 @ pH 7.2) at room temperature with gentle
agitation to ensure oxygenation. Each part received either
inhibitor (ucf-101) or equal volume DMSO. The inhibitor ucf-
101 (EMD Chemicals #496150) was dissolved in DMSO.
Commercially available recombinant HtrA2 (#1458-HT) was
purchased from R&D Systems and digestion studies were done
according to the manufacturer’s protocol.
Protein separation and detection
Mitochondrial proteins were solubilised via freeze-thaw repeats
in the presence of 1% Triton X-100. Insoluble matter was
removed by centrifugation. IEF was performed on a Protean
BioRad according to the manufacturer’s instructions. Proteins that
required concentration were done so using a PALL 3K mini-
column. PAGE was performed after IEF on Criterion pre-cast
IPG-gels. Gels were silver stained using SilverSNAP stain for Mass
Spectrometry (Pierce #24600) and quantified using ImageJ
(included as supplementary information S1). Separation via 1D
PAGE was performed on Invitrogen pre-cast gels with Western
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Invitrogen blotter. All immunoblots were blocked in 2% BSA.
Antibodies were purchased from Sigma (anti-FLAG #F7425),
R&D systems (anti-Omi/HtrA2 #AF1458), Molecular Probes
(anti-PDHB #A-21323), Everest (anti-HSPA8 #EB07295) and
(Abgent anti-IDH3A #AP1927). Fluorescent secondary antibodies
were purchased from Molecular Probes (#A11001, A21428,
A21235 or A21432). HRP-conjugated secondary antibodies were
purchased from Pierce (#18584) or Amersham (NA934V). FLAG-
tagged OMI monomers were immunoprecipitated using EZview
Red Anti-FLAG Affinity Gel beads (Sigma #A2220). Endogenous
HSPA8 was immunoprecipitated using Sepharose Protein A beads
(Sigma #P3391) to which the antigen-anti-HSPA8 antibody
complexes were bound, according to the manufacturer’s protocol
with modified centrifuge speeds which were kept below 4,000 Xg.
HA-tagged HSPA8 was immunoprecipitated using EZView Red
Anti-HA affinity gel (Sigma#E6779) and eluted using Influenza
hemagglutinin (HA) peptide (Sigma#I2149) according to the
manufacturer’s protocol with the exception of the centrifuge
speeds as stated previously. The size (approximately 61 kDa) of the
HA.HSPA8 corresponded to isoform 2 with a short additional pre-
sequence (from the UTR) and the HA sequence.
RNA extraction, cDNA synthesis and qPCR
Total RNA was extracted from cells using the TriZOL method
(Invitrogen #15596-026). Synthesis of cDNA from 1 ug of RNAt
was achieved using the iScript kit (BioRad #170-8891). Analysis of
gene expression was performed on an ABI Prism7000 with CYBR
Green and gene specific primers. All results were normalized to b-
actin, before being expressed as a percentage of the control
(untreated) sample. Concentrations of toxins were chosen from our
previous studies.
Supporting Information
Supplementary Information S1 All spots were corrected for
background using the integrated density (ImageJ software). In
Table S1 and S2 LDH and Spot #4, of the (-) ucf-101 and
OMI.S306C/G399S gels respectively, were , background,
denoted here as ‘‘neg’’. Control spots were chosen arbitrarily to
compare overall loading densities. In all cases the FLAG.
OMI.S306C control spots were less concentrated than those in
OMI double mutant samples, implying the intensity of the
identified spots was under-estimated by approximate factor of 2
to 2.5X. The (-) ucf-101 control spots were slightly greater or
slightly less concentrated than their equivalent in the (+) ucf-101.
Found at: doi:10.1371/journal.pone.0007100.s001 (0.02 MB
DOC)
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